Hans Biomed
한스바이오메드 · 042520
Health Care Pharmaceuticals · KOSDAQ
Market cap US$271.8M (₩375.1B)
Overview
Hans Biomed makes human tissue implants, grafts derived from skin and bone used in surgical procedures, as well as medical devices such as thread-lift products and hair-transplant tools.
Its products are used by medical professionals, and it supplies customers both in South Korea and internationally through subsidiaries in the United States, Thailand, the United Kingdom, and other markets. Listed on KOSDAQ, South Korea's tech and small-cap exchange, the company earns the majority of its revenue from its tissue-implant product lines, with medical devices accounting for most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$56.5M
- FY2024US$58.8M
- FY2025US$65.1M
Operating profit
- FY2023−US$3M
- FY2024US$453.3K
- FY2025−US$18.8M
Net income
- FY2023−US$17.5M
- FY2024−US$5.7M
- FY2025−US$23.2M
Key ratios (FY2025)
Why it matters
The company also has affiliated domestic entities and conducts R&D across tissue engineering and newer fields such as vascular haemostasis devices through shared research centres.
Price charts coming soon
Interactive price history isn't here yet. Would you use it?